Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
J Cancer Res Clin Oncol ; 149(20): 18065-18080, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37982828

ABSTRACT

BACKGROUND: This work aimed to prepare niosomal formulations of an anticancer agent [mefenamic acid (MEF)] to enhance its cancer targeting. 131I was utilized as a radiolabeling isotope to study the radio-kinetics of MEF niosomes. METHODS: niosomal formulations were prepared by the ether injection method and assessed for entrapment efficiency (EE%), zeta potential (ZP), polydispersity index (PDI) and particle size (PS). MEF was labeled with 131I by direct electrophilic substitution reaction through optimization of radiolabeling-related parameters. In the radio-kinetic study, the optimal 131I-MEF niosomal formula was administered intravenously (I.V.) to solid tumor-bearing mice and compared to I.V. 131I-MEF solution as a control. RESULTS: the average PS and ZP values of the optimal formulation were 247.23 ± 2.32 nm and - 28.3 ± 1.21, respectively. The highest 131I-MEF labeling yield was 98.7 ± 0.8%. The biodistribution study revealed that the highest tumor uptake of 131I-MEF niosomal formula and 131I-MEF solution at 60 min post-injection were 2.73 and 1.94% ID/g, respectively. CONCLUSION: MEF-loaded niosomes could be a hopeful candidate in cancer treatment due to their potent tumor uptake. Such high targeting was attributed to passive targeting of the nanosized niosomes and confirmed by radiokinetic evaluation.


Subject(s)
Liposomes , Neoplasms , Mice , Animals , Mefenamic Acid , Tissue Distribution , Neoplasms/diagnostic imaging , Neoplasms/drug therapy
2.
Curr Drug Deliv ; 20(4): 387-399, 2023.
Article in English | MEDLINE | ID: mdl-35339176

ABSTRACT

BACKGROUND: 5-azacitidine is a very potent chemotherapeutic agent that suffers from certain disadvantages. OBJECTIVE: This study aims to prepare gold nanoparticles as a new nano-formula of 5-azacitidine that can improve its bioavailability and decrease its side effects. METHODS: 5-azacytidine-loaded GA-AuNPs were prepared and characterized by UV-Vis spectroscopy, infrared (IR), and electronic transmission microscope (TEM). This new platform was characterized in vitro by measuring its zeta potential, particle size, and drug loading efficacy, and the anti-proliferative effect on the MCF-7 cell line was evaluated. In vivo biodistribution studies of 99mTc-5-aza solution and 99mTc-5-aza-gold nano formula were conducted in tumor-bearing mice by different routes of administration (intravenous and intra-tumor). RESULTS: 5-Aza-GA-AuNPs formula was successfully prepared with an optimum particle size of ≈34.66 nm, the zeta potential of -14.4 mV, and high entrapment efficiency. 99mTc-5-Aza-GA-AuNPs were successfully radiosynthesized with a labeling yield of 95.4%. Biodistribution studies showed high selective accumulation in tumor and low uptake in non-target organs in the case of the 5-Aza-GA-AuNPs formula than the 99mTc-5-azacitidine solution. CONCLUSION: 99mTc-5-Aza-GA-AuNPs improved the selectivity and uptake of 5-azacitidine in cancer. Moreover, 99mTc-5-Aza-GA-AuNPs could be used as hopeful theranostic radiopharmaceutical preparation for cancer.


Subject(s)
Gold , Metal Nanoparticles , Mice , Animals , Gold/chemistry , Azacitidine/pharmacology , Tissue Distribution , Metal Nanoparticles/chemistry , Radiopharmaceuticals , Technetium/chemistry , Technetium/pharmacology
3.
Int J Pharm ; 628: 122345, 2022 Nov 25.
Article in English | MEDLINE | ID: mdl-36349611

ABSTRACT

A niosomal formula of acemetacin was developed to improve its tumor targeting and radio-kinetic evaluation was performed using 131I. Niosomes were prepared by ether injection method and characterized for particle size (PS), polydispersity index (PDI), zeta potential (ZP), entrapment efficiency (EE%) and in vitro drug release. Factors affecting radiolabeling with 131I were studied and optimized. Radio-kinetic evaluation was done for 131I-ACM optimum niosomal formula by intravenous (I.V) administration to solid tumor bearing mice and compared to I.V 131I-ACM solution as a control. The average droplet size, zeta potential and in vitro release after 24 h for the optimum formula were 315.23 ± 5.37 nm, -9.16 ± 2.91 and 76 %, respectively. The greatest labeling yield of 131I-ACM was 93.1 ± 1.1 %. Radio-kinetic evaluation showed a maximum tumor uptake of 5.431 %ID/g for 131I-ACM niosomal formula and 2.601 %ID/g for 131I-ACM solution at 60 min post I.V. injection. As a conclusion, niosomal formula increased tumor uptake of ACM by passive targeting of the nanosized niosomes. In addition, chemotherapeutic effect of ACM and radiotherapeutic effect of 131I were successfully combined in one treatment regimen using 131I-ACM niosomes which could be used as a hopeful dual anticancer therapy.


Subject(s)
Iodine Radioisotopes , Liposomes , Animals , Mice , Particle Size
4.
J Labelled Comp Radiopharm ; 64(14): 534-547, 2021 12.
Article in English | MEDLINE | ID: mdl-34582054

ABSTRACT

Nanoparticles are frequently used as targeting delivery systems for therapeutic and diagnostic radiopharmaceuticals. Polyethylene oxide-polyacrylic acid (PEO-PAAc) nanogel was prepared via γ-radiation-induced polymerization. Variable factors affecting nanoparticles size were investigated. The nanogel was radiolabeled with the imaging radioisotope 99m Tc and finally conjugated with folic acid to target folate receptor actively. PEO-PAAc-folic acid gel was characterized by dynamic light scattering (DLS) and atomic force microscopy (AFM). Biodistribution was studied in normal mice and solid tumor-bearing mice via intravenous and intratumor injections of the radiolabeled PEO-PAAc-folic acid nanogel. Results of biodistribution showed high selective uptake of the prepared complex in tumor muscle compared with normal muscle for both intravenous and intratumor injections. The T/NT ratio was found to be 6.186 and 294.5 for intravenous and intratumor injections, respectively. Consequently, 99m Tc-PEO-PAAc-folic acid complex could be a promising agent for cancer diagnostic imaging.


Subject(s)
Folic Acid , Neoplasms , Acrylic Resins , Animals , Cell Line, Tumor , Diagnostic Imaging , Mice , Nanogels , Neoplasms/diagnostic imaging , Polyethylene Glycols , Radiopharmaceuticals , Technetium , Tissue Distribution
5.
Bioorg Chem ; 92: 103282, 2019 11.
Article in English | MEDLINE | ID: mdl-31541801

ABSTRACT

Bisphosphonates are widely used for treatment of osteoporosis. Recently, they have been reported to be effective anticancer agents. In this work, we designed some substituted phenyl (azanediyl) bis (methylene phosphonic acid) to be tested for their anticancer effect. Both molecular docking and dynamics studies were used to select the top ranked highly scored compounds. The selected hits showed potential in vitro anticancer effect against some cell lines. Biodistribution pattern and gamma scintigraphy were conducted to the most effective derivative (BMBP) after radiolabeling with 99mTc. Results of biodistribution and scintigraphic imaging of 99mTc-BMBP in tumor bearing mice showed a notable tumor affinity, and confirmed the targeting affinity of BMBP to the tumor tissues. As a conclusion, BMBP could act as potential anticancer agent and imaging probe.


Subject(s)
Adenocarcinoma, Bronchiolo-Alveolar/drug therapy , Antineoplastic Agents/pharmacology , Aza Compounds/pharmacology , Enzyme Inhibitors/pharmacology , Lung Neoplasms/drug therapy , Optical Imaging , Phosphorous Acids/pharmacology , A549 Cells , Adenocarcinoma, Bronchiolo-Alveolar/diagnostic imaging , Adenocarcinoma, Bronchiolo-Alveolar/metabolism , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Aza Compounds/chemical synthesis , Aza Compounds/chemistry , Cell Proliferation/drug effects , Dose-Response Relationship, Drug , Drug Design , Drug Screening Assays, Antitumor , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , Gamma Rays , Geranyltranstransferase/antagonists & inhibitors , Geranyltranstransferase/metabolism , Humans , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/metabolism , Models, Molecular , Molecular Structure , Phosphorous Acids/chemical synthesis , Phosphorous Acids/chemistry , Structure-Activity Relationship , Tissue Distribution
6.
Mol Pharm ; 16(10): 4190-4199, 2019 10 07.
Article in English | MEDLINE | ID: mdl-31509423

ABSTRACT

The purpose of our study was to improve the delivery of a direct-acting antiviral drug, daclatasvir, to the site of action, liver tissues, using physically and biologically stable cationic bile-based vesicles. Accordingly, cationic bile-based vesicles were prepared as pro-bile-based vesicles and diethylaminoethyl dextran (DEAE-Dx)-stabilized bile-based vesicles to increase their stability without negatively affecting their hepatic affinity. The prepared bile-based vesicles were characterized for particle size, polydispersity index, ζ-potential, in vitro daclatasvir release, and ex vivo permeation using non-everted gut sac intestine. The in vivo biodistribution was experimented after oral administration utilizing the radiolabeling assay, where the liver showed the highest accumulation of the DEAE-Dx-stabilized bile-based vesicles after 4 h, reaching a value of 4.6% ID/g of the total oral administered dose of the labeled drug compared to drug solution, pro-bile-based vesicles, and cationic bile-based vesicles where the accumulation was 0.19, 1.3, and 0.31% ID/g, respectively. DEAE-Dx-stabilized bile-based vesicles increased the drug deposition into the liver about 42-fold compared to oral solution. The high physical stability and the high resistance to opsonization and clearance show that DEAE-Dx-stabilized bile-based vesicles could be efficiently applied for enhancing daclatasvir delivery to the liver after oral administration.


Subject(s)
Bile Acids and Salts/chemistry , Cations/chemistry , DEAE-Dextran/chemistry , Drug Delivery Systems , Imidazoles/metabolism , Liposomes/administration & dosage , Liver/metabolism , Animals , Biological Availability , Carbamates , Drug Carriers/chemistry , Imidazoles/administration & dosage , Intestinal Mucosa/drug effects , Intestinal Mucosa/metabolism , Liposomes/chemistry , Male , Mice , Permeability , Pyrrolidines , Rats , Rats, Wistar , Tissue Distribution , Valine/analogs & derivatives
7.
Eur J Pharm Sci ; 121: 29-33, 2018 08 30.
Article in English | MEDLINE | ID: mdl-29787786

ABSTRACT

Selective receptors imaging using gamma emitting radiopharmaceuticals allows accurate diagnosis and follow up of many brain related disorders. Levetiracetam, a selective SV2A receptor antiepileptic, was successfully radiolabeled using 99mTc. Different conditions affecting the labelling process were studied and optimum radiochemical yield of 89.8% was obtained. 99mTc-levetiracetam was effectively formulated and characterized as microemulsion with particle size of 16.34 ±â€¯5.58 nm and polydispersity index of 0.382 ±â€¯0.05. Parallel biodistribution studies were performed comparing brain targeting efficiency of I.V 99mTc-levetiracetam solution, I.N 99mTc-levetiracetam solution and I.N 99mTc-levetiracetam microemulsion. Brain radioactivity uptake and brain/blood uptake ratio for I.N 99mTc-levetiracetam microemulsion were higher than the other two routes at all time intervals. Such results present intranasal 99mTc-levetiracetam microemulsion as the first SPECT tracer for imaging SV2A receptor.


Subject(s)
Brain/metabolism , Levetiracetam/chemistry , Membrane Glycoproteins/metabolism , Nerve Tissue Proteins/metabolism , Organotechnetium Compounds/chemistry , Radiopharmaceuticals/chemistry , Administration, Intranasal , Animals , Drug Compounding , Emulsions , Levetiracetam/administration & dosage , Levetiracetam/pharmacokinetics , Male , Mice , Organotechnetium Compounds/administration & dosage , Organotechnetium Compounds/pharmacokinetics , Radioactive Tracers , Radiopharmaceuticals/administration & dosage , Radiopharmaceuticals/pharmacokinetics , Tissue Distribution , Tomography, Emission-Computed, Single-Photon
8.
Eur J Med Chem ; 151: 723-739, 2018 May 10.
Article in English | MEDLINE | ID: mdl-29665526

ABSTRACT

The current work presents the synthesis and biological evaluation of new series of coumarin hydrazide-hydrazone derivatives that showed in vitro broad spectrum antitumor activities against resistant pancreatic carcinoma (Panc-1), hepatocellular carcinoma (HepG2) and leukemia (CCRF) cell lines using doxorubicin as reference standard. Bromocoumarin hydrazide-hydrazone derivative (BCHHD) 11b showed excellent anticancer activity against all tested cancer cell lines. Enzyme assays showed that BCHHD 11b induced apoptosis due to activation of caspases 3/7. Moreover, 11b inhibited GST and CYP3A4 in a dose dependent manner and the induced cell death could be attributed to metabolic inhibition. Moreover, 11b microarray analysis showed significant up- and down-regulation of many genes in the treated cells related to apoptosis, cell cycle, tumor growth and suppressor genes. All of the above presents BCHHD 11b as a potent anticancer agent able to overcome drug resistance. In addition, compound 11b was able to serve as a chemical carrier for 99mTc and the in vivo biodistribution study of 99mTc-11b complex revealed a remarkable targeting ability of 99mTc into solid tumor showing that 99mTc-11b might be used as a promising radiopharmaceutical imaging agent for cancer.


Subject(s)
Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Coumarins/chemistry , Coumarins/pharmacology , Hydrazones/chemistry , Hydrazones/pharmacology , Animals , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/pharmacokinetics , Cell Line, Tumor , Coumarins/chemical synthesis , Coumarins/pharmacokinetics , Cytochrome P-450 CYP3A/metabolism , Cytochrome P-450 CYP3A Inhibitors/chemical synthesis , Cytochrome P-450 CYP3A Inhibitors/chemistry , Cytochrome P-450 CYP3A Inhibitors/pharmacokinetics , Cytochrome P-450 CYP3A Inhibitors/pharmacology , Halogenation , Humans , Hydrazones/chemical synthesis , Hydrazones/pharmacokinetics , Mice , Neoplasms/drug therapy , Neoplasms/metabolism , Neoplasms/pathology , Tissue Distribution
9.
Molecules ; 23(2)2018 Feb 23.
Article in English | MEDLINE | ID: mdl-29473879

ABSTRACT

l-Phosphinothricin (glufosinate or 2-amino-4-((hydroxy(methyl) phosphinyl) butyric acid ammonium salt (AHPB)), which is a structural analog of glutamate, is a recognized herbicide that acts on weeds through inhibition of glutamine synthetase. Due to the structural similarity between phosphinothricin and some bisphosphonates (BPs), this study focuses on investigating the possibility of repurposing phosphinothricin as a bisphosphonate analogue, particularly in two medicine-related activities: image probing and as an anti-cancer drug. As BP is a competitive inhibitor of human farnesyl pyrophosphate synthase (HFPPS), in silico molecular docking and dynamic simulations studies were established to evaluate the binding and stability of phosphinothricin with HFPPS, while the results showed good binding and stability in the active site of the enzyme in relation to alendronate. For the purpose of inspecting bone-tissue accumulation of phosphinothricin, a technetium (99mTc)-phosphinothricin complex was developed and its stability and tissue distribution were scrutinized. The radioactive complex showed rapid, high and sustained uptake into bone tissues. Finally, the cytotoxic activity of phosphinothricin was tested against breast and lung cancer cells, with the results indicating cytotoxic activity in relation to alendronate. All the above results provide support for the use of phosphinothricin as a potential anti-cancer drug and of its technetium complex as an imaging probe.


Subject(s)
Aminobutyrates/chemistry , Antineoplastic Agents/chemistry , Drug Repositioning , Radiopharmaceuticals/chemistry , Technetium/chemistry , Alendronate/chemistry , Aminobutyrates/pharmacology , Animals , Antineoplastic Agents/pharmacology , Binding Sites , Cell Line, Tumor , Cell Proliferation/drug effects , Diagnostic Imaging , Drug Stability , Humans , Hydrogen-Ion Concentration , Mice , Molecular Docking Simulation , Molecular Dynamics Simulation , Molecular Structure , Radiopharmaceuticals/pharmacology , Structure-Activity Relationship , Technetium/pharmacology , Tissue Distribution
10.
Drug Deliv ; 23(9): 3681-3695, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27648847

ABSTRACT

Clonazepam (CZ) is an anti-epileptic drug used mainly in status epilepticus (SE). The drug belongs to Class II according to BCS classification with very limited solubility and high permeability and it suffers from extensive first-pass metabolism. The aim of the present study was to develop CZ-loaded polymeric micelles (PM) for direct brain delivery allowing immediate control of SE. PM were prepared via thin film hydration (TFH) technique adopting a central composite face-centered design (CCFD). The seventeen developed formulae were evaluated in terms of entrapment efficiency (EE), particle size (PS), polydispersity index (PDI), zeta potential (ZP), and in vitro release. For evaluating the in vivo behavior of the optimized formula, both biodistrbution using 99mTc-radiolabeled CZ and pharmacodynamics studies were done in addition to ex vivo cytotoxicty. At a drug:Pluronic® P123:Pluronic® L121 ratio of 1:20:20 (PM7), a high EE, ZP, Q8h, and a low PDI was achieved. The biodistribution studies revealed that the optimized formula had significantly higher drug targeting efficiency (DTE = 242.3%), drug targeting index (DTI = 144.25), and nose-to-brain direct transport percentage (DTP = 99.30%) and a significant prolongation of protection from seizures in comparison to the intranasally administered solution with minor histopathological changes. The declared results reveal the ability of the developed PM to be a strong potential candidate for the emergency treatment of SE.


Subject(s)
Brain/drug effects , Clonazepam/administration & dosage , Clonazepam/chemistry , Polymers/chemistry , Status Epilepticus/drug therapy , Administration, Intranasal/methods , Animals , Chemistry, Pharmaceutical/methods , Drug Carriers/chemistry , Drug Delivery Systems/methods , Male , Mice , Micelles , Nasal Mucosa/metabolism , Particle Size , Poloxamer/chemistry , Sheep , Solubility , Tissue Distribution
11.
Drug Deliv ; 23(9): 3374-3386, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27128792

ABSTRACT

Migraine attack is a troublesome physiological condition associated with throbbing, intense headache, in one half of the head. Zolmitriptan is a potent second-generation triptan, prescribed for patients with migraine attacks, with or without an aura, and cluster headaches. The absolute bioavailability of zolmitriptan is about 40% for oral administration; due to hepatic first metabolism. Nasal administration would circumvent the pre-systemic metabolism thus increasing the bioavailability of zolmitriptan. In addition, due to the presence of microvilli and high vasculature, the absorption is expected to be faster compared to oral route. However, the bioavailability of nasal administered drugs is particularly restricted by poor membrane penetration. Thus, the aim of this work is to explore the potential of novel nanovesicular fatty acid enriched structures (novasomes) for effective and enhanced nasal delivery of zolmitriptan and investigate their nose to brain targeting potential. Novasomes were prepared using nonionic surfactant, cholesterol in addition to a free fatty acid. A 23 full factorial design was adopted to study the influence of the type of surfactant, type of free fatty acid and ratio between the free fatty acid and the surfactant on novasomes properties. The particle size, entrapment efficiency, polydispersity index, zeta potential and % zolmitriptan released after 2 h were selected as dependent variables. Novasomes were further optimized using Design Expert® software (version 7; Stat-Ease Inc., Minneapolis, MN), and an optimized formulation composed of Span® 80:Cholesterol:stearic acid (in the ratio 1:1:1) was selected. This formulation showed zolmitriptan entrapment of 92.94%, particle size of 149.9 nm, zeta potential of -55.57 mV, and released 48.43% zolmitriptan after 2 h. The optimized formulation was further examined using transmission electron microscope, which revealed non-aggregating multi-lamellar nanovesicles with narrow size distribution. DSC, XRD examination of the optimized formulation confirmed that the drug have been homogeneously dispersed throughout the novasomes in an amorphous state. In-vivo bio-distribution studies of 99mTc radio-labeled intranasal zolmitriptan loaded novasomes were done on mice, the pharmacokinetic parameters were compared with those following administration of intravenous 99mTc-zolmitriptan solution. Results revealed the great enhancement in zolmitriptan targeting to the brain, with drug targeting potential of about 99% following intranasal administration of novasomes compared with the intravenous drug solution. Zolmitriptan loaded novasomes administered via the nasal route may therefore constitute an advance in the management of acute migraine attacks.


Subject(s)
Brain/drug effects , Nasal Mucosa/metabolism , Oxazolidinones/administration & dosage , Tryptamines/administration & dosage , Administration, Intranasal/methods , Administration, Oral , Animals , Chemistry, Pharmaceutical/methods , Drug Delivery Systems/methods , Male , Mice , Migraine Disorders/drug therapy , Oxazolidinones/chemistry , Particle Size , Surface-Active Agents/chemistry , Tryptamines/chemistry
12.
Drug Deliv ; 24(1): 181-187, 2016 Nov.
Article in English | MEDLINE | ID: mdl-28156162

ABSTRACT

Nimodipine (NM) is the only FDA-approved drug for treating subarachnoid hemorrhage induced vasospasm. NM has poor oral bioavailability (5-13%) due to its low aqueous solubility, and extensive first pass metabolism. The objective of this study is to develop radiolabeled NM-loaded LPM and to test its ability prolong its circulation time, reduce its frequency of administration and eventually target it to the brain tissue. NM was radiolabeled with 99mTc by direct labeling method using sodium dithionite. Different reaction conditions that affect the radiolabeling yield were studied. The in vivo pharmacokinetic behavior of the optimum NM-loaded LPM formulation in blood, heart, and brain tissue was compared with NM solution, after intravenous and intranasal administration. Results show that the radioactivity percentage (%ID/g) in the heart of mice following administration of 99mTc-NM loaded LPM were lower compared with that following administration of 99mTc-NM solution, which is greatly beneficial to minimize the cardiovascular side effects. Results also show that the %ID/g in the blood, and brain following intravenous administration of 99mTc-NM-loaded LPM were higher at all sampling intervals compared with that following intravenous administration of 99mTc-NM solution. This would be greatly beneficial for the treatment of neurovascular diseases. The drug-targeting efficiency of NM to the brain after intranasal administration was calculated to be 1872.82%. The significant increase in drug solubility, enhanced drug absorption and the long circulation time of the NM-loaded LPM could be promising to improve nasal and parenteral delivery of NM.


Subject(s)
Calcium Channel Blockers/administration & dosage , Drug Carriers/administration & dosage , Excipients/administration & dosage , Nimodipine/administration & dosage , Phosphatidylcholines/administration & dosage , Poloxamer/administration & dosage , Vasodilator Agents/administration & dosage , Administration, Intranasal , Animals , Biological Availability , Blood-Brain Barrier/metabolism , Calcium Channel Blockers/blood , Calcium Channel Blockers/metabolism , Calcium Channel Blockers/pharmacokinetics , Drug Carriers/metabolism , Drug Carriers/pharmacokinetics , Drug Compounding , Excipients/chemistry , Half-Life , Injections, Intravenous , Mice , Micelles , Nanotechnology , Nimodipine/blood , Nimodipine/metabolism , Nimodipine/pharmacokinetics , Particle Size , Phosphatidylcholines/chemistry , Poloxalene/administration & dosage , Poloxalene/chemistry , Poloxamer/chemistry , Solubility , Technetium , Tissue Distribution , Vasodilator Agents/blood , Vasodilator Agents/metabolism , Vasodilator Agents/pharmacokinetics
SELECTION OF CITATIONS
SEARCH DETAIL
...